Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,
Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,
#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms
Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Apostolidis L
Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,
Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,
Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,
Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Apostolidis L, Bergmann F, Haag G, Jäger D, Winkler E,
Keywords: MiNEN, mixed neuroendocrine non-neuroendocrine neoplasm, MANEC, mixed adenoneuroendocrine carcinoma,
Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Winkler E, Mehlis K, Kudlich M, Apostolidis L, Witte J,
Keywords: financial toxicity, economic burden, patient-reported outcome, distress, quality of life,